Association Between Statin Usage and Mortality Outcomes in Aging U.S. Cancer Survivors: a Nationwide Cohort Study

Overview

Journal Aging Clin Exp Res

Publisher Springer

Specialty Geriatrics

Date 2024 Oct 7

PMID 39373829

Authors

Shan Ding

Fengling Yang

Pan Lai

Weiwen Jiang

Minze Chen

Yijun Ge

Liting Zhou

Shaozhuang Chen

Jiaqi Zhang

Yanrong Ye

Affiliations

Soon will be listed here.

Abstract

Background: The population of Aging cancer survivors in the United States has surged to over 16.9 million. Research on the relationship between statin usage and post-cancer survival rates remains limited.

Aims: This study aims to investigate the association between statin use and various causes of mortality among aging cancer survivors.

Methods: We analyzed NHANES data from 1999 to 2018, Statin usage, both hydrophilic and lipophilic, was derived from NHANES prescription records. We utilized Cox proportional hazards models to associate statin utilization with mortality, differentiating causes of death according to statin type and patterns of use.

Results: Within a cohort of 2,968 participants, statin usage was categorized into non-users (1,738), hydrophilic statin users (216), and lipophilic statin users (982). Compared to those who did not use statins, individuals prescribed hydrophilic statins did not show a reduced risk of all-cause mortality (adjusted hazard ratio [HR] 1.01; 95% confidence interval [CI] 0.72-1.41; P = 0.960), as outlined in Model 3. In contrast, the group receiving lipophilic statins exhibited a notable decrease in all-cause mortality risk (adjusted HR, 0.77; P = 0.003). Nonetheless, both hydrophilic and lipophilic statins were effective in diminishing the risk associated with cancer from its onset until death, with hydrophilic statins showing a greater level of efficacy.

Discussion: The potential of statins to reduce cancer-related mortality may provide avenues for targeted clinical interventions and management strategies.

Conclusions: Our study reveals that the use of lipophilic statins is significantly associated with lower all-cause and cancer-cause mortality risks among aging cancer survivors.

References

Zhang Y, Liang M, Sun C, Qu G, Shi T, Min M . Statin Use and Risk of Pancreatic Cancer: An Updated Meta-analysis of 26 Studies. Pancreas. 2019; 48(2):142-150. DOI: 10.1097/MPA.0000000000001226. View

Bonovas S, Filioussi K, Tsavaris N, Sitaras N . Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005; 23(34):8606-12. DOI: 10.1200/JCO.2005.02.7045. View

Fong C . Statins in therapy: understanding their hydrophilicity, lipophilicity, binding to 3-hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies. Eur J Med Chem. 2014; 85:661-74. DOI: 10.1016/j.ejmech.2014.08.037. View

Kim B, Hong S, Lee Y, Hong S, Yun K, Hong B . Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022; 400(10349):380-390. DOI: 10.1016/S0140-6736(22)00916-3. View

Jakobisiak M, Golab J . Potential antitumor effects of statins (Review). Int J Oncol. 2003; 23(4):1055-69. View

Hicks C, Wang D, Matsushita K, Windham B, Selvin E . Peripheral Neuropathy and All-Cause and Cardiovascular Mortality in U.S. Adults : A Prospective Cohort Study. Ann Intern Med. 2020; 174(2):167-174. PMC: 7932559. DOI: 10.7326/M20-1340. View

MacDonald T, Davis K, Tucker W, Miketinas D . Serum Cholesterol Differences Between Statin Users Who Take Dietary Supplements and Those Who Do Not: NHANES 2013-2018. Curr Dev Nutr. 2023; 7(1):100007. PMC: 10100929. DOI: 10.1016/j.cdnut.2022.100007. View

Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L . Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016; 388(10059):2532-2561. DOI: 10.1016/S0140-6736(16)31357-5. View

Okedele O, Nelson H, Oyenuga M, Thyagarajan B, Prizment A . Cytomegalovirus and cancer-related mortality in the national health and nutritional examination survey. Cancer Causes Control. 2020; 31(6):541-547. DOI: 10.1007/s10552-020-01296-y. View

10.

Pourlotfi A, Bass G, Ahl Hulme R, Forssten M, Sjolin G, Cao Y . Statin Use and Long-Term Mortality after Rectal Cancer Surgery. Cancers (Basel). 2021; 13(17). PMC: 8428352. DOI: 10.3390/cancers13174288. View

11.

Scott O, TinTin S, Harborg S, Kuper-Hommel M, Lawrenson R, Elwood J . Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study. Breast Cancer Res Treat. 2023; 199(1):195-206. PMC: 10147735. DOI: 10.1007/s10549-022-06815-w. View

12.

Kuoppala J, Lamminpaa A, Pukkala E . Statins and cancer: A systematic review and meta-analysis. Eur J Cancer. 2008; 44(15):2122-32. DOI: 10.1016/j.ejca.2008.06.025. View

13.

Bardou M, Barkun A, Martel M . Effect of statin therapy on colorectal cancer. Gut. 2010; 59(11):1572-85. DOI: 10.1136/gut.2009.190900. View

14.

Menter D, Ramsauer V, Harirforoosh S, Chakraborty K, Yang P, Hsi L . Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PLoS One. 2012; 6(12):e28813. PMC: 3245236. DOI: 10.1371/journal.pone.0028813. View

15.

Gupta K, Kakar T, Jain V, Gupta M, Al Rifai M, Slipczuk L . Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey. Prog Cardiovasc Dis. 2022; 75:78-82. DOI: 10.1016/j.pcad.2022.08.007. View

16.

Hamelin B, Turgeon J . Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998; 19(1):26-37. DOI: 10.1016/s0165-6147(97)01147-4. View

17.

Facciorusso A, Abd El Aziz M, Singh S, Pusceddu S, Milione M, Giacomelli L . Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis. Cancers (Basel). 2020; 12(4). PMC: 7225931. DOI: 10.3390/cancers12040874. View

18.

An Y, Sun J, Xu M, Liu C, Xu J, Zhong X . Statin Use Is Associated with Better Prognosis of Patients with Prostate Cancer after Definite Therapies: A Systematic Review and Meta-Analysis of Cohort Studies. J Oncol. 2022; 2022:9275466. PMC: 9681552. DOI: 10.1155/2022/9275466. View

19.

Poynter J, Gruber S, Higgins P, Almog R, Bonner J, Rennert H . Statins and the risk of colorectal cancer. N Engl J Med. 2005; 352(21):2184-92. DOI: 10.1056/NEJMoa043792. View

20.

Chang W, Lin H, Lin S, Li Y . Association of Statin Use With Cancer- and Noncancer-Associated Survival Among Patients With Breast Cancer in Asia. JAMA Netw Open. 2023; 6(4):e239515. PMC: 10122177. DOI: 10.1001/jamanetworkopen.2023.9515. View